Skip to main content
Top
Published in:

Open Access 05-05-2024 | Correction

Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Authors: Kerstin Wimmer, Dominik Hlauschek, Marija Balic, Georg Pfeiler, Richard Greil, Christian F. Singer, Stefan Halper, Günther Steger, Christoph Suppan, Simon P. Gampenrieder, Ruth Helfgott, Daniel Egle, Martin Filipits, Raimund Jakesz, Lidija Sölkner, Christian Fesl, Michael Gnant, Florian Fitzal

Published in: Breast Cancer Research and Treatment | Issue 2/2024

Login to get access

Excerpt

Correction to: Breast Cancer Research and Treatment https://doi.org/10.1007/s10549-023-07186-6
Metadata
Title
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Authors
Kerstin Wimmer
Dominik Hlauschek
Marija Balic
Georg Pfeiler
Richard Greil
Christian F. Singer
Stefan Halper
Günther Steger
Christoph Suppan
Simon P. Gampenrieder
Ruth Helfgott
Daniel Egle
Martin Filipits
Raimund Jakesz
Lidija Sölkner
Christian Fesl
Michael Gnant
Florian Fitzal
Publication date
05-05-2024
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2024
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-024-07351-5

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now